Cognate BioServices expands manufacturing in U.S., Europe Contract development and manufacturing organization Cognate BioServices plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and to increase office support at its facilities in the U.S. and Europe.
Development 'cookbooks' could speed up gene therapy Great strides have been made in the development of gene editing tools in the past decade, but translating the technology into real therapies to treat patients has taken longer than expected. How to accelerate this process was the subject of a panel discussion on January 13 at the Biotech Showcase virtual event. Discuss
Lentigen to manufacture vector for Oncternal Oncternal Therapeutics announced an agreement with Lentigen Technology, a subsidiary of Miltenyi Biotec, to manufacture lentiviral vectors for Octernal's investigational receptor tyrosine kinase-like orphan receptor 1-targeting chimeric antigen receptor T-cell therapy program.
Cytovia licenses CAR NK tech to NCI Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its gene-edited induced pluripotent stem cell-derived technology to develop glypican-3 (GPC3) chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics.
Taysha, UTSW start fund to speed up CNS gene therapies Taysha Gene Therapies and the University of Texas Southwestern Medical Center (UTSW) have launched a fund to accelerate the development of adeno-associated virus gene therapies for monogenic diseases of the central nervous system (CNS).